UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/517,981	07/14/2005	Michel Maillard	02-415-A1	3761	
20306 7590 02/04/2008 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE			EXAMINER		
			ROGERS, JUNE MARIE		
•	32ND FLOOR CHICAGO, IL 60606		ART UNIT	PAPER NUMBER	
<b>-</b>			4173		
			MAIL DATE	DELIVERY MODE	
			02/04/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/517,981	MAILLARD ET AL.			
		Examiner	Art Unit			
		JUNE ROGERS	4173			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY WHICHEVER IS LONGER, FF - Extensions of time may be available und after SIX (6) MONTHS from the mailing ( - If NO period for reply is specified above, - Failure to reply within the set or extended	COM THE MAILING DA er the provisions of 37 CFR 1.13 late of this communication. the maximum statutory period w d period for reply will, by statute, n three months after the mailing	'IS SET TO EXPIRE 1 MONTH ATE OF THIS COMMUNICATIO 6(a). In no event, however, may a reply be ti rill apply and will expire SIX (6) MONTHS fron cause the application to become ABANDON date of this communication, even if timely file	N. imely filed must be mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
·—	2b)⊠ This in condition for allowar	_ action is non-final. nce except for formal matters, pr x parte Quayle, 1935 C.D. 11, 4	•			
Disposition of Claims						
4) ⊠ Claim(s) <u>1-6, 9, 11-14, 2</u> 4a) Of the above claim(s) 5) □ Claim(s) is/are all 6) □ Claim(s) is/are re 7) □ Claim(s) is/are ob 8) ⊠ Claim(s) <u>1-6, 9, 11-14, 2</u>	) is/are withdrav owed. iected. ijected to.		election requirement.			
Application Papers						
	is/are: a) accellinate any objection to the elet(s) including the correction	epted or b) objected to by the drawing(s) be held in abeyance. So ion is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment(s)  1) Notice of References Cited (PTO-89 2) Notice of Draftsperson's Patent Drav 3) Information Disclosure Statement(s) Paper No(s)/Mail Date	ving Review (PTO-948)	4) Interview Summar Paper No(s)/Mail [5] Notice of Informal 6) Other:				

Application/Control Number: 10/517,981

Art Unit: 4173

### **DETAILED ACTION**

### Restriction

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 4-6, 20, 22, 23 and 25-30, drawn to a method of treating various diseases

Group II, claim(s), 9, drawn to a method of inhibiting beta-secretase activity

Group III, claim(s) 11-14, drawn to a method of inhibiting production of amyloid beta peptide in a cell

The inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons: the compounds employed are already known in the prior art and each formulation comprises compounds having different variable core structures and corresponding functionalities.

Application/Control Number: 10/517,981 Page 3

Art Unit: 4173

Specifically, Maibaum et al. (US 5,641,778) discloses various compounds of formula I (see abstract). Additionally, the substituents on the structure vary extensively and when taken as a whole result in vastly different compounds.

In conclusion, there is a lack of unity of inventions and therefore restriction for examination purposed as indicated is proper.

# Species Election

Claims 1-6, 9, 11-14, 20, 22- 23 and 25-30 are generic to the following disclosed patentably distinct species:

- (1) A compound of formula I
- (2) A compound of formula I-A
- (3) Various diseases

The species are independent or distinct because as disclosed the different species have mutually exclusive characteristics for each identified species. In addition, these species are not obvious variants of each other based on the current record.

Art Unit: 4173

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

**Specifically,** if Applicant elects the invention of Group I, II, or III Applicant is required to define each of R1, R2, and R3 and *any additional variables* as required for a single specific specie of a compound in claim 5 or claim 22.

<u>Additionally</u>, if applicant elects the invention of Group I, Applicant is further required to elect a single specific specie of disease to be treated.

There is an examination and search burden for these patentably distinct species due to their mutually exclusive characteristics. The species require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another species; and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Accordingly, <u>Applicants are required</u> to make a provisional election of (i) a single independent and/or patentably distinct Invention stated supra prior to an examination of said species on the merits (ii) an election of a species to be examined even though the requirement may be traversed (37 CFR 1.143) and (iii) identification of the claims encompassing the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

## Inventorship Notice

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Application/Control Number: 10/517,981

Art Unit: 4173

Page 6

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JUNE ROGERS whose telephone number is (571)270-3497. The examiner can normally be reached on M-F 9-6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Fred Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Juné M. Rogers